Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week

We recently published a list of These 10 Stocks Just Rocked The Market. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other stocks that just rocked the market.

Regeneron Pharmaceuticals declined by 16.7 percent last week as investors sold off positions amid the surprising failure of its potential treatment for chronic obstructive pulmonary disease (COPD) in one of its late-stage trials.

According to Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), the first trial of the Phase 3 study for the efficacy of itepekimab in adult former smokers with COPD met the primary target of showing a 27-percent reduction in the worsening symptoms after 52 weeks. However, the second trial failed to meet the same endpoint, having reduced by only 2 percent during the same study period.

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), along with its partner, Sanofi, said that they are reviewing the data and will discuss with regulatory authorities to evaluate next steps.

“Certain people with COPD are in desperate need of new treatment options, especially those who continue to experience exacerbations despite being on maximal therapy, and we remain committed to discussing these data with regulatory agencies to evaluate our path forward,” said Sanofi Head of Research and Development Houman Ashrafian.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.